SCHEMBL984737

SCHEMBL984737

COc1ccc(C2=NN(C(=O)Cc3cccs3)CC2)c(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
TSHR P16473 1/20 0.47
GFER P55789 1/20 0.43
PKM P14618 2/20 0.42
GAA P10253 2/20 0.42
YAP1 P46937 1/20 0.42
TEAD4 Q15561 1/20 0.42
TEAD2 Q15562 1/20 0.42
ATM Q13315 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 2/20 0.41
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.39
RAB9A P51151 1/20 0.39
MAOB P27338 1/20 0.39
HTT P42858 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984588 0.86 SMN1; SMN2 (0.54) POLBSMN1; SMN2TSHRGFERPKM
SCHEMBL983114 0.85 MEN1 (0.52) POLBSMN1; SMN2TSHRGFERPKM
SCHEMBL980224 0.83 KMT2A (0.45) SMN1; SMN2PKMGAAMEN1KMT2A
SCHEMBL981501 0.77 KMT2A (0.42) POLBSMN1; SMN2TSHRGFERPKM
SCHEMBL982034 0.77 ALDH1A1 (0.50) POLBSMN1; SMN2PKMGAAYAP1
SCHEMBL982164 0.73 KDM4E (0.48) POLBSMN1; SMN2PKMMEN1KMT2A
SCHEMBL981784 0.73 ALDH1A1 (0.49) POLBSMN1; SMN2PKMMEN1KMT2A
SCHEMBL982617 0.73 ALDH1A1 (0.53) POLBSMN1; SMN2PKMGAAMEN1
SCHEMBL981499 0.72 ALDH1A1 (0.45) POLBSMN1; SMN2GFERPKMGAA
SCHEMBL982365 0.70 KDM4E (0.55) POLBPKMMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 POLB 3230/4885SMN1; SMN2 4245/4885TSHR 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.